Navigation Links
Microbia Announces Name Change to Ironwood Pharmaceuticals
Date:4/7/2008

CAMBRIDGE, Mass., April 7, 2008 /PRNewswire/ -- Microbia, Inc. today announced that it has changed its name to Ironwood Pharmaceuticals, Inc. The ironwood is a long-lived tree that thrives in the harshest desert environment, with some trees surviving as long as 1,500 years. Known as a "nurse tree," it provides a shaded microclimate with lower temperatures, higher water availability, and more organic matter for birds, reptiles, insects, animals, and plants. In addition, the name Ironwood encompasses the inorganic and organic -- the properties of essential elements and the characteristics of life.

"As Microbia has developed and progressed, we have outgrown the usefulness of the name Microbia," said Peter Hecht, CEO. "With that in mind, we sought a name for the company that reflects our approach to creating important human medicines. Because our research efforts are not limited to a single therapeutic area, we require a name that will accommodate a broad range of discoveries and products. We chose a name that not only suits us today, but also can endure for 100 years."

Additional information can be found at http://www.ironwoodpharma.com.

About Ironwood Pharmaceuticals (formerly Microbia)

Ironwood Pharmaceuticals (http://www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. The Company is advancing several clinical candidates -- linaclotide for the treatment of irritable bowel syndrome with constipation, chronic constipation and other functional gastrointestinal disorders; and novel, next-generation cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Microbia Precision Engineering, Inc., a majority-owned subsidiary of Ironwood Pharmaceuticals is an industrial biotechnology company developing and commercializing novel bioprocesses for the production of specialty chemicals. Ironwood has raised $231 million in private equity financing and is located in Cambridge, Massachusetts.

Contact:

Susan Brady

Corporate Communications

617|621-8304

sbrady@ironwoodpharma.com


'/>"/>
SOURCE Microbia, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Microbial Genome-to-Array Service
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
4. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
5. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
6. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
7. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
8. Medicsight Announces New Marketing Partnership with INFINITT
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
11. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... Well, look no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering ... need to give mom an experience she won’t forget. , Guests that visit ...
(Date:5/4/2016)... ... ... Proove Biosciences, Inc. , the commercial and research leader in personalized pain ... partnership is designed to advance research in pain genetics in an effort to bring ... new agreement, researchers at Proove Biosciences are able to collaborate with Luda Diatechnko, MD, ...
(Date:5/4/2016)... , May 4, 2016  Bayer today ... oncology compound Stivarga ® (regorafenib) tablets for ... (HCC) has met its primary endpoint of a ... called RESORCE, evaluated the efficacy and safety of ... progressed after treatment with sorafenib. The safety and ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, 2016 , ... ... neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the ... treatment or cure. , Through numerous community events held during the month of May, ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):